Company: ACBM
Filing Date: 2025-07-24
Form Type: 10-K
Source: 0001640334-25-001300
Chunk: 149

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-07-24
Form: 10-K
Item: Item 16
Chunk 149
---
Not applicable

 28Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ACRO BIOMEDICAL CO., LTD. Date: July 24, 2025By:/s/ Pao-Chi Chu Name:Pao-Chi Chu Title:Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. 

SignatureTitleDate/s/ Pao-Chi ChuDirector, chief executive officer and July 24, 2025Pao-Chi Chuchief financial officer (principal executive, financial and accounting officer)

 29Table of Contents

ACRO BIOMEDICAL CO., LTD.

Index to Financial Statements

 Page Reports of Independent Registered Public Accounting Firms (PCAOB ID 2851) F-2 Balance Sheets at December 31, 2024 and 2023 F-3 Statements of Operations for the years ended December 31, 2024 and 2023  F-4 Statements of Changes in Stockholders’ Equity (Deficit) for the years ended December 31, 2024 and 2023  F-5 Statements of Cash Flows for the years ended December 31, 2024 and 2023  F-6 Notes to Financial Statements F-7

 F-1Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Stockholders and Board of Directors of

Acro Biomedical Co., Ltd.

Opinion on the Financial Statements

We have audited the accompanying balance sheets of Acro Biomedical Co., Ltd. (the “Company") as of December 31, 2024 and 2023, and the related statements of operations, changes in stockholders' equity (deficit) and cash flows for the years then ended, and related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles